Publications by authors named "L Perlee"
Article Synopsis
- CHAPLE disease is a rare and serious condition affecting fewer than 100 young people worldwide, characterized by symptoms like abdominal pain and protein loss from the intestines.
- A study used mixed methods, including interviews and clinical assessments, to evaluate the impact of pozelimab treatment on these symptoms over 24 weeks.
- Results showed that after treatment, patients experienced complete resolution of core symptoms, highlighting the value of mixed-methods in understanding patient experiences in rare disease trials.
Article Synopsis
- CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE) is a rare genetic disorder that affects the intestines and causes serious complications due to excessive complement system activity.
- The study evaluated the safety and efficacy of pozelimab, an antibody that blocks a specific part of this system, in ten patients diagnosed with CHAPLE across three countries: Thailand, Türkiye, and the USA.
- Results focused on the proportion of patients whose serum albumin normalized and showed clinical improvement after 24 weeks of treatment, with assessments conducted to monitor any worsening of inactive symptoms.
Purpose: To compare intravitreal nesvacumab (anti-angiopoietin-2) + aflibercept vs intravitreal aflibercept injection (IAI) in neovascular age-related macular degeneration (nAMD).
Methods: Eyes were randomized (1:2:3) to nesvacumab 3 mg + aflibercept 2 mg (LD combo), nesvacumab 6 mg + aflibercept 2 mg (HD combo), or IAI 2 mg at baseline, week 4, and week 8. The LD combo was continued every 8 weeks (q8w).
The common γ chain (γc; IL-2RG) is a subunit of the interleukin (IL) receptors for the γc cytokines IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. The lack of appropriate neutralizing antibodies recognizing IL-2RG has made it difficult to thoroughly interrogate the role of γc cytokines in inflammatory and autoimmune disease settings. Here, we generated a γc cytokine receptor antibody, REGN7257, to determine whether γc cytokines might be targeted for T cell-mediated disease prevention and treatment.
View Article and Find Full Text PDFBackground: The dominant allergen in cat dander, Felis domesticus allergen 1 (Fel d 1), is a persistent trigger for allergic rhinitis and asthma symptoms.
Objective: We evaluated the efficacy of Fel d 1 monoclonal antibodies (REGN1908/1909) in preventing cat allergen-induced early asthmatic responses (EARs) in cat-allergic patients with mild asthma.
Methods: Patients were randomized to single-dose REGN1908/1909 600 mg (n = 29) or placebo (n = 27).